We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
Cap. Flow
-$71.1M
Cap. Flow %
-2.5%
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$12.2M
2
SYK icon
Stryker
SYK
+$10.9M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.83M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.51M
5
BDX icon
Becton Dickinson
BDX
+$8.08M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$36.7M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.4M
3
MRK icon
Merck
MRK
+$16.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.4M
5
DHR icon
Danaher
DHR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Real Estate 3.21%
3 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLYB icon
51
Rallybio
RLYB
$84.8M
$15.3M 0.54%
274,376
-14,208
-5% -$1.18M
CVS icon
52
CVS Health
CVS
$133B
$14.9M 0.52%
147,453
– –
UTHR icon
53
United Therapeutics
UTHR
$22B
$13M 0.45%
72,206
-29,531
-29% -$5.63M
KRTX
54
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$12.7M 0.45%
100,458
– –
ACH
55
Accendra Health
ACH
$224M
$12.7M 0.45%
288,167
– –
ARGX icon
56
argenx
ARGX
$53B
$12.1M 0.43%
38,456
– –
NVS icon
57
Novartis
NVS
$291B
$12M 0.42%
136,225
– –
NBIX icon
58
Neurocrine Biosciences
NBIX
$17B
$11.7M 0.41%
124,609
– –
LH icon
59
Labcorp
LH
$25.2B
$11.6M 0.41%
51,381
– –
RARE icon
60
Ultragenyx Pharmaceutical
RARE
$2.54B
$10.2M 0.36%
140,726
– –
APLS
61
DELISTED
Apellis Pharmaceuticals
APLS
$9.95M 0.35%
195,820
– –
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$11.7B
$9.87M 0.35%
128,004
– –
ONC
63
BeOne Medicines Ltd
ONC
$33.6B
$9.62M 0.34%
51,018
-12,754
-20% -$2.71M
OHI icon
64
Omega Healthcare
OHI
$14.5B
$9.55M 0.34%
306,433
– –
QURE icon
65
uniQure
QURE
$3.07B
$9.43M 0.33%
521,693
– –
A icon
66
Agilent Technologies
A
$39.3B
$8.85M 0.31%
66,845
+27,220
+69% +$3.75M
WAT icon
67
Waters Corp
WAT
$38.6B
$8.83M 0.31%
28,461
– –
MPT
68
Medical Properties Trust
MPT
$2.77B
$8.7M 0.31%
411,743
– –
DOC
69
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.7M 0.31%
495,733
– –
XBI icon
70
State Street SPDR S&P Biotech ETF
XBI
$9.93B
$8.6M 0.3%
+95,649
New +$8.83M
BHVN
71
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.32M 0.29%
70,176
– –
ALGN icon
72
Align Technology
ALGN
$12.3B
$8.24M 0.29%
18,894
+11,435
+153% +$5.57M
ASND icon
73
Ascendis Pharma A/S
ASND
$16.1B
$7.96M 0.28%
67,794
– –
ADUS icon
74
Addus HomeCare
ADUS
$2.14B
$7.8M 0.27%
83,632
– –
SBRA icon
75
Sabra Healthcare REIT
SBRA
$5.16B
$7.6M 0.27%
510,660
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
  • Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
  • Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
  • Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
  • Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
  • Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
  • Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.